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*Author for correspondence (e-mail: dlinzer@nwu.edu)We previously demonstrated that the zinc finger transcrip-
tion factors GATA-2 and GATA-3 are expressed in tro-
phoblast giant cells and that they regulate transcription
from the mouse placental lactogen I gene promoter in a
transfected trophoblast cell line. We present evidence here
that both of these factors regulate transcription of the
placental lactogen I gene, as well as the related proliferin
gene, in trophoblast giant cells in vivo. Placentas lacking
GATA-3 accumulate placental lactogen I and proliferin
mRNAs to a level 50% below that reached in the wild-type
placenta. Mutation of the GATA-2 gene had a similar effect
on placental lactogen I expression, but led to a markedly
greater reduction (5- to 6-fold) in proliferin gene
expression. Placentas lacking GATA-2 secrete significantly
less angiogenic activity than wild-type placentas as
measured in an endothelial cell migration assay, consistent
with a reduction in expression of the angiogenic hormone
proliferin. Furthermore, within the same uterus the
decidual tissue adjacent to mutant placentas displays
markedly reduced neovascularization compared to the
decidual tissue next to wild-type placentas. These results
indicate that GATA-2 and GATA-3 are important in vivo
regulators of trophoblast-specific gene expression and
placental function, and reveal a difference in the effect of
these two factors in regulating the synthesis of related
placental hormones.
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SUMMARYINTRODUCTION
The trophectoderm, the outer layer of the blastocyst, is the first
cell lineage to differentiate in the mammalian embryo (Ilgren,
1983). Upon migration away from the inner cell mass, some
trophoctoderm cells further differentiate into trophoblast giant
cells (Müntener and Hsu, 1977; Ilgren, 1983), which have
amplified, polytene genomes (Varmuza et al., 1988). The giant
cells produce a number of placental hormones, including four
members of the prolactin (PRL)/growth hormone (GH) family
in the mouse: placental lactogen I (PL-I), placental lactogen II
(PL-II), proliferin (PLF), and proliferin-related protein (PRP)
(Ogren and Talamantes, 1988). PL-I and PL-II bind to the PRL
receptor (Harigaya et al., 1988; MacLeod et al., 1989) and
enhance the maintenance of the corpus luteum, regulate
maternal carbohydrate metabolism in the liver, and stimulate
the development of the mammary gland for postpartum
lactation (Ogren and Talamantes, 1988). PLF and PRP, which
bind neither the PRL receptor nor the GH receptor, are major
positive and negative regulators, respectively, of angiogenesis
(Jackson et al., 1994); PLF has also been found to stimulate
uterine cell proliferation (Nelson et al., 1995).
Analysis of the expression of two of these hormones, PL-I
and PLF, may be especially useful in characterizing early
molecular events underlying trophoblast differentiation, since
transcription of the PL-I and PLF genes occurs exclusively ingiant cells and begins at the time of implantation (Lee et al.,
1988; Nieder and Jennes, 1990; Faria et al., 1991; Carney et
al., 1993). The temporal patterns of PL-I and PLF expression
are very similar, with peak mRNA and protein levels for both
of these hormones occurring on day 10 of gestation (Linzer et
al, 1985; Colosi et al., 1987; Lee et al., 1988; Ogren et al.,
1989). Thus, the PL-I and PLF genes may have critical tran-
scriptional regulatory elements in common and may be under
the coordinate control of one or a small number of regulatory
factors.
Our previous studies on the PL-I gene have identified a region
of only 274 bp immediately upstream of the transcriptional start
site that is sufficient for trophoblast-specific expression in trans-
fected cell cultures (Shida et al., 1993). Within this region are
regulatory elements recognized by the AP-1 transcription factor
(Shida et al., 1993) and by two members of the GATA family
of transcription factors, GATA-2 and GATA-3 (Ng et al., 1994).
Both the AP-1 sites and the GATA sites are critical for promoter
activity in transfected Rcho-1 cells (Shida et al., 1993; Ng et
al., 1994), a rat choriocarcinoma cell line that differentiates in
culture into hormone-producing giant cells (Faria and Soares,
1991). Furthermore, we have demonstrated that GATA-2 and
GATA-3 are expressed in trophoblast giant cells; that increased
levels of GATA-2 and GATA-3 result in greater transcriptional
activity of the PL-I promoter in Rcho-1 cells, indicating that
these factors are present in limiting amounts; and that the
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converts those cells into a permissive environment for PL-I
promoter activity, suggesting that these factors may positively
and directly contribute to trophoblast giant cell differentiation
(Ng et al., 1994).
The analysis of the PLF gene promoter has also revealed a
critical AP-1 element (Mordacq and Linzer, 1989; Groskopf
and Linzer, 1994) and the presence of GATA-2/3 consensus
binding sites (Ng et al., 1994). The locations of the AP-1 and
GATA sites with respect to the transcription start site are
similar in the PLF and PL-I gene promoters. Furthermore, in
both promoters one of the GATA elements is in close proximity
to an AP-1 site, suggesting that these factors might work
together in a complex regulating the expression of both of these
genes.
GATA-2 and GATA-3 are expressed in distinct but overlap-
ping patterns during embryonic development (Yamamoto et al.,
1990; Dorfman et al., 1992; Oosterwegel et al., 1992; Leonard
et al., 1993; George et al., 1994; Ng et al., 1994). Gene dis-
ruption experiments revealed that both GATA-2 and GATA-3
are required for fetal development, with GATA-2 essential for
hematopoiesis (Tsai et al., 1994) and GATA-3 for fetal nervous
system development and fetal liver hematopoiesis (Pandolfi et
al., 1995). However, since these factors are also expressed in
the placenta and have been implicated in placental-specific
gene expression (Ng et al., 1994; Steger et al., 1994), it is
possible that disruption of the GATA-2 or GATA-3 genes also
has significant consequences on placental development and
function. To explore this possibility, PL-I and PLF gene
expression have been examined in mice bearing targeted
mutations in the GATA-2 or GATA-3 gene. These studies
indicate that both GATA-2 and GATA-3 are required for
maximal PL-I and PLF expression in vivo. 
MATERIALS AND METHODS
Animals
Mice heterozygous for a disrupted GATA-2 gene (Tsai et al., 1994)
were mated, and pregnant female mice were killed on day 9.5 of
gestation. Similarly, mice heterozygous for a disrupted GATA-3 gene
(Pandolfi et al., 1995) were mated, and pregnant females were killed
at day 10.5 or 11.5. The day of appearance of a vaginal plug was des-
ignated as day 0.5. Mice were maintained on a cycle of 14 hours
light/10 hours dark, with food and water freely available. All pro-
cedures were approved by the Animal Care and Use Committee.
Genotype determination
Embryos and placentas were separated, rapidly frozen on dry ice, and
stored at - 80°C. Genomic DNA was extracted from embryos or yolk
sacs as described by Hogan et al. (1994). Samples were digested in
100 m l of proteinase K (2 mg/ml in 50 mM Tris-HCl, pH 9.0, 50 mM
EDTA, 400 mM NaCl, 5 mM DTT, 2.5 mM spermidine, and 1% SDS)
at 55°C overnight. The lysate was extracted with phenol/chloroform
and the DNA was precipitated with ethanol. GATA-2 and GATA-3
genotypes were analyzed by PCR (Tsai et al., 1994; Pandolfi et al.,
1995). Briefly, 0.2 m g of genomic DNA was combined with 0.2 mM
each of dATP, dCTP, dGTP and dTTP, 1 m M of each primer, 1· PCR
buffer (1.5 mM MgCl2, 50 mM KCl, 20 mM Tris-HCl, pH 8.4, 0.1
mg/ml gelatin), and 0.5 units of AmpliTaq DNA polymerase (Perkin-
Elmer, Foster City, CA) in a 20 m l volume. After 32-35 cycles, PCR
products from the wild-type and mutant alleles were detected by
agarose gel electrophoresis.RNA isolation and filter hybridization
Total RNA was isolated from selected placentas based on the geno-
typing results. For RNA isolation, placental tissue was homogenized
in guanidinium thiocyanate, and the lysate was purified by centrifu-
gation through a CsCl cushion (Ausubel et al., 1995). 5 m g of total
RNA were denatured and subjected to formaldehyde-agarose gel elec-
trophoresis. RNA was then transferred onto nitrocellulose membranes,
immobilized by UV cross-linking, and hybridized to radiolabeled PL-
I (Colosi et al., 1987), PLF (Linzer and Nathans, 1984), or ribosomal
protein S2 (Harpold et al., 1979) cDNAs. Hybridization intensities
were quantified by phosphorimaging, and the amount of the ribosomal
protein S2 mRNA was used for normalization.
In situ hybridization
In situ hybridization was performed on frozen placental tissue as pre-
viously described (Ng et al., 1994). Tissue sections (10-20 m m) were
cut, fixed in 5% paraformaldehyde, and acetylated. Antisense and
sense riboprobes for PL-I and PLF were synthesized by in vitro tran-
scription using SP6 or T7 RNA polymerase to incorporate [a -
35S]UTP and purified by Sephadex G-50 column chromatography.
Sections were hybridized with 107 cpm/ml of riboprobe at 47°C in
heavy mineral oil chambers. After a 12- to 16-hour hybridization,
slides were treated with RNase A (20 m g/ml) at 37°C for 30 minutes.
Slides were washed progressively in 1· SSC, 0.5· SSC, and 0.25·
SSC at 47°C, then coated with NTB-2 emulsion and exposed for two
weeks at 4°C. After development, slides were stained with hema-
toxylin.
To determine the number of giant cells, tissue sections were stained
in 0.2 m g/ml 4¢ ,6-diamidino-2-phenylindole (DAPI, from Sigma
Chemical Company, St. Louis, MO) solution for 10 minutes at room
temperature followed by washing in phosphate-buffered saline.
Stained, giant nuclei were counted by fluorescence microscopy.
Placental cultures and endothelial cell migration
Conceptuses arising from matings of mice heterozygous at the GATA-
2 locus were isolated on day 9.5 of gestation. Fetal tissue was used
for genotyping, and the corresponding placentas were minced and
placed into culture in 0.5 ml serum-free Dulbecco’s Modified Eagle’s
Medium (DMEM, GIBCO-BRL, Grand Island, NY). Culture media
were collected after 24 hours, clarified by centrifugation, and protein
concentrations were determined by a dye binding assay (BioRad,
Hercules, CA).
Primary cultures of bovine adrenal capillary endothelial cells were
propagated in DMEM supplemented with 10% fetal calf serum and
endothelial cell mitogen (100 m g/ml) (Biomedical Technologies,
Stoughton, MA). Cells to be used for migration assays were incubated
overnight in DMEM without serum but with 0.1% bovine serum
albumin (BSA), and then transferred to gelatinized 0.5 mm filters
(Nucleopore Corporation, Pleasanton, CA) in a Boyden chamber at
1.3· 104 cells per well. The upper chambers contained DMEM with
0.1% BSA, and the lower chambers DMEM with each sample (5
m g/ml placental conditioned medium or 10 ng/ml basic fibroblast
growth factor, bFGF, as a positive control). After 6 hours at 37°C, the
filters were removed from the chambers, fixed and stained, and the
number of cells that had migrated to the lower surface of each filter
was determined.
Immunostaining of blood vessels
Conceptuses arising from matings of mice heterozygous at the GATA-
2 locus were isolated on day 9.5 of gestation. Fetal tissue was excised
and used for genotyping. The remaining tissue, including the placenta
and the associated decidual tissue from the uterus, was immediately
frozen, sectioned and fixed in paraformaldehyde. Tissue sections were
treated with an antibody against the endothelial cell surface marker
PECAM-1 (Vecchi et al., 1994), and antibody binding was visualized
using the Vectastain kit (Vector Laboratories, Burlingame, CA).
Sections were then counterstained with hematoxylin.
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Fig. 2. Temporal pattern of hormone
gene expression in GATA-3 mutant
placentas. Total placental RNA at day
10.5 and day 11.5 of gestation was
analyzed by filter hybridization to the
PL-I (top panel) or PLF (middle panel)
cDNA, or to the control ribosomal
protein S2 cDNA (bottom panel). The
heterozygous (+/- ) or homozygous (- /- )
GATA-3 mutant genotype is indicated
for each of the placental samples.RESULTS
Placental gene expression in mice lacking GATA-3
To investigate the in vivo role of GATA factors in the
expression of trophoblast-specific genes, mice heterozyygous
for a disrupted GATA-3 gene were mated, and placental and
fetal tissue were harvested at day 10.5 of gestation, the time of
peak synthesis of both PL-I and PLF. Since the trophoblast
lineage derives from the embryo and not from the mother, these
matings were expected to yield, within each litter, placentas
and embryos that are wild type, heterozygous, or homozygous
mutant at the GATA-3 locus. RNA was purified from each
placenta to analyze hormone mRNA levels; DNA was
extracted from the corresponding fetus in each case and
analyzed by PCR to determine the genotype.
Placentas that develop without GATA-3 express the PL-I and
PLF mRNAs (Fig. 1), suggesting that GATA-3 is not
absolutely required for trophoblast giant cell differentiation.
However, the levels of both of these mRNAs are reduced in
these placentas, indicating that GATA-3 is required for
maximal PL-I and PLF gene expression. The analysis of five
litters (three are shown in Fig. 1) revealed that PL-I mRNA
levels are higher in wild type (2.3±0.2-fold after normalization
to the ribosomal protein S2 mRNA, n=5) and heterozygotes
(2.7±0.3-fold, n=5) than in the homozygous mutants. A similar
effect was observed on PLF expression, with wild type
(1.8±0.3-fold, n=5) and heterozygous (2.0±0.2-fold, n=5)
placentas containing higher concentrations of this mRNA than
the homozygous mutant placentas. No significant differences
in PL-I and PLF mRNA levels were detected between het-
erozygous mutant and wild-type placentas, and no change was
seen in the amount of the control ribosomal protein S2 mRNA
among the three genotypes. Some variation in the level of
hormone gene expression from litter to litter was observed,
though, probably in part because of the narrow window of
maximal PL-I and PLF gene expression and because the litters
were of slightly different gestational ages; comparisons were
therefore always made within individual litters.
Temporal pattern of placental hormone gene
expression
One explanation for the decreased level of PL-I and PLF
mRNAs in GATA-3 homozygous mutant placentas might beFig. 1. Hormone mRNA levels in GATA-3 mutant placentas. Total
placental RNA from day 10.5 of gestation was analyzed by
sequential filter hybridization to PL-I (top panel), PLF (middle
panel), and control ribosomal protein S2 (bottom panel) cDNAs.
Wild-type (+/+), heterozygous GATA-3 mutant (+/- ), or
homozygous GATA-3 mutant (-/-) placental RNA samples from three
litters (Roman numerals) were assayed.that the absence of GATA-3 resulted in a shift in the temporal
pattern of hormone gene expression such that the peak levels
of PL-I and PLF mRNA, which normally occur on day 10, are
delayed. However, the amount of PL-I mRNA rapidly declines
between day 10.5 and day 11.5 in wild type (not shown), het-
erozygous, and homozygous mutant placentas, and the level at
day 11.5 is still greater in the heterozygous placenta compared
to the homozygous mutant placenta (Fig. 2). Although the con-
centration of PLF mRNA does not decline as rapidly as PL-I
mRNA, decreased levels are detected from day 10.5 to day 11.5
in all three genotypes, as well, (shown for heterozygous and
homozygous mutant samples in Fig. 2) and again, the het-
erozygous placenta has a higher concentration of PLF mRNA
compared to the homozygous mutant placenta. Thus, the
absence of GATA-3 results in decreased expression of the PL-
I and PLF genes, rather than a delay in their expression.
Placental gene expression in mice lacking GATA-2
The 2-fold decrease in PL-I mRNA levels seen in the GATA-
3 mutant background was also observed for placentas in which
the GATA-2 gene had been disrupted (Fig. 3); the ratio of PL-
I mRNA in wild-type compared to homozygous mutant
placentas was found to be 2.7±0.6 (n=5), and 1.9±0.2 (n=5) for
heterozygous compared to homozygous mutant placentas. In
contrast, mutation of the GATA-2 gene had a more pronounced
effect on PLF gene expression than did the disruption of the
GATA-3 gene (Fig. 3); the ratio of PLF mRNA in wild type
compared to homozygous mutant placentas was found to be
6.2±1.2 (n=5), and 4.7±0.6 (n=5) for heterozygous compared
to homozygous mutant placentas. For this analysis, RNA levelsFig. 3. Hormone mRNA levels in GATA-2 mutant placentas. Total
placental RNA from day 9.5 of gestation was analyzed by sequential
filter hybridization to the PL-I (top panel) or PLF (middle panel)
cDNA, or to the control ribosomal protein S2 cDNA (bottom panel).
Roman numerals indicate three distinct litters, and the wild-type
(+/+), heterozygous mutant (+/-), or homozygous mutant (- /- )
GATA-2 genotype is indicated for each of the placental samples.
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Fig. 4. PL-I gene expression in GATA-3 mutant trophoblast giant
cells. Wild-type (A-C) or homozygous GATA-3 mutant (D-F)
placentas were sectioned and hybridized to the PL-I antisense (A-B
and D-E) or control sense (C,F) riboprobes. Hybridization, detected
as dark silver grains in the bright-field photomicrographs (A,D) or as
bright regions in the dark-field images (B,E), is seen specifically in
the trophoblast giant cells. No hybridization was detected in the
surrounding uterine cells or in other cell types within the placenta,
and no hybridization was observed with the sense probes (C,F). The
height of each panel in the figure corresponds to a distance of
0.6 mm.
Fig. 5. PLF gene expression in GATA-3 mutant trophoblast giant cells. Wild-
type (A-B) or homozygous GATA-3 mutant (C-D) placentas were sectioned
and hybridized to a PLF antisense riboprobe. Hybridization is detected in the
trophoblast giant cells as dark silver grains in the bright-field
photomicrographs (A,C) or as bright regions in the dark-field images (B,D);
no hybridization was detected in other cell types, and no hybridization was
observed with a control sense probe (not shown). The height of each panel in
the figure corresponds to a distance of 0.6 mm.were measured at day 9.5 of gestation since GATA-2
homozygous mutants die on day 10 (Tsai et al., 1994).
PL-I and PLF gene expression in individual
trophoblast giant cells
The reduction in PL-I and PLF gene expression in
GATA factor-deficient placentas could be due to a
decrease in hormone synthesis within each trophoblast
giant cell, to a decrease in the number of giant cells, or
to a combination of these two effects. To address this
question, placental tissue from wild type and mutant lit-
termates was analyzed by in situ hybridization. Hybrid-
ization of placental tissue with a PL-I probe revealed
that expression of the PL-I mRNA is still restricted to
the giant cells in the homozygous GATA-3 mutant
placenta, but that the level of PL-I mRNA in each giant
cell is reduced relative to the wild-type placenta (Fig. 4).
Similarly, less PLF mRNA appears to be present per
giant cell in the homozygous mutant GATA-3 placenta
compared to wild type (Fig. 5). An apparently greater
reduction in PL-I (Fig. 6) and PLF (Fig. 7) mRNA levels
in each trophoblast giant cell is seen in the GATA-2
homozygous mutant placenta.
Although the size of the giant cell layer in the GATA-
3 and GATA-2 homozygous mutants often appears to be
reduced, no significant difference was detected between
the number of giant cell nuclei in wild-type andhomozygous mutant placentas as determined by counting of
DAPI-stained sections. The number of giant cell nuclei per
section from three pairs (i.e., in the same pregnant female) of
wild-type and homozygous mutant placentas were calculated
as the mean ± standard deviation from up to eight sections with
the following results: 130±22 (wild type) and 136±13 (mutant);
114±9 (wild type) and 125±18 (mutant); and 238±29 (wild
type) and 213±31 (mutant); the variation in the number of
nuclei seen between pairs was probably due to slight differ-
ences in gestational ages. In addition to the finding that the
number of giant cells is indistinguishable in the wild-type and
mutant placentas, inspection of the morphology of the giant
cell layer did not reveal and gross structural defects. These
results indicate that the reduced level of PL-I and PLF mRNA
in placentas lacking GATA-3 or GATA-2 can be attributed
primarily to decreased gene expression within each giant cell.
Reduced angiogenic activity of GATA-2 deficient
placentas
PLF stimulates endothelial cell migration and neovasculariza-
tion, and is therefore thought to stimulate the growth of
maternal uterine blood vessels towards the conceptus (Jackson
et al., 1994). Since PLF represents the majority of the angio-
genic activity secreted from the mid-gestation placenta in an
endothelial cell migration assay (Jackson et al., 1994), it
seemed likely that the total angiogenic activity secreted by
GATA-2 mutant placentas, which have very low PLF mRNA
levels, would be greatly reduced.
To examine this hypothesis, tissue from three homozygous
mutant placentas and from three wild-type or heterozygous
mutant placentas was cultured in serum-free medium. The con-
ditioned media from the three homozygous mutant placenta
cultures had significantly less stimulatory activity in the endo-
thelial cell migration assay than the conditioned media from
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Fig. 6. PL-I gene expression in GATA-2 mutant trophoblast
giant cells. Wild-type (A,B) or homozygous GATA-2 mutant
(C,D) placentas were sectioned and hybridized to a PL-I
antisense riboprobe. Hybridization to the trophoblast giant cells
is detected as dark silver grains in the bright-field
photomicrographs (A,C) or as bright regions in the dark-field
images (B,D); no hybridization was detected in other cell types,
and no hybridization was observed with a control sense probe
(not shown). The height of each panel in the figure corresponds
to a distance of 0.6 mm.
F gene expression in GATA-2 mutant trophoblast giant cells. Wild-
) or homozygous GATA-2 mutant (C,D) placentas were sectioned and
d to a PLF antisense riboprobe. Hybridization is detected in the
st giant cells as dark silver grains in the bright-field photomicrographs
s bright regions in the dark-field images (B,D); no hybridization was
n other cell types, and no hybridization was observed with a control
be (not shown). The height of each panel in the figure corresponds to a
f 0.6 mm.the wild-type or heterozygous placenta cultures (Fig. 8). Some
residual activity was detected in the homozygous mutant
samples, consistent with the presence of other angiogenic
factors (Jackson et al., 1994). Thus, one consequence of the
absence of GATA-2 in the developing placenta is a deficiency
in the secretion of angiogenic factors, possibly leading to
abnormal placental and decidual vascularization.
The in vivo consequences of reduced placental angiogenic
activity was analyzed by comparing neovascularization in
decidual tissue adjacent to wild-type and homozygous GATA-
2 mutant conceptuses within individual pregnant females. Fetal
tissue from the conceptuses was excised to determine the
genotype of the placenta. Neovascularization in the decidual
tissue associated with each conceptus was visualized by
immunostaining with an antibody against an endothelial cell
surface protein, PECAM-1. A significant reduction in neovas-
cularization in the decidual tissue adjacent to the
mutant conceptuses is seen compared to the growth
of blood vessels in the uterus near wild-type concep-
tuses (Fig. 9).
DISCUSSION
The present analysis of mice lacking the GATA-2 or
GATA-3 transcription factors has demonstrated that
both of these factors are required for maximal
expression of both the PL-I and PLF genes in vivo.
We had previously shown that both factors regulate
PL-I promoter activity in co-transfected Rcho-1 cells
(Ng et al., 1994), so the current results support the use
of this rat trophoblast cell line as a model system for
studying trophoblast gene expression. Since the PL-I
and PLF genes are co-expressed in trophoblast giant
cells at the same stage of gestation, these results
further suggest that GATA-2 and GATA-3 may coor-
dinately control the transcription of a set of genes in
giant cells, and therefore may be important regulators
of trophoblast giant cell differentiation. However, dis-
ruption of neither the GATA-2 nor the GATA-3 gene
alone was sufficient to prevent giant cell differen-
tiation, suggesting that these factors may have com-
plementary activities and that mutation of both genes
Fig. 7. PL
type (A,B
hybridize
trophobla
(A,C) or a
detected i
sense pro
distance omay be necessary to observe a requirement for GATA factors
in placental development. Attempts to produce mice that are
heterozygous mutant at both the GATA-2 and GATA-3 loci
have yielded the surprising result that the double heterozygous
embryos die during gestation, and therefore it is not currently
possible to generate mice null for both GATA-2 and GATA-3
to test this hypothesis; the basis for this fetal lethality in the
double heterozygotes is under investigation.
Even though GATA-2 and GATA-3 may have overlapping
activities, disruption of the GATA-2 gene was found to have a
more pronounced effect on PLF gene expression than did
mutation of the GATA-3 gene. One possible explanation is that
GATA-2 and GATA-3 have identical activities on this gene
promoter, but that in the wild-type placenta GATA-2 protein is
simply more abundant than GATA-3. In this case, the effects
of these factors could be additive and total GATA factor activity
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Fig. 8. Angiogenic activity secreted by GATA-2
mutant placentas. Cultures of placental tissue from
day 9.5 of gestation were prepared from two
separate litters with (A) one wild-type (+/+), one
heterozygous mutant (+/- ), and one homozygous
mutant (- / - ) GATA-2 placenta, or (B) one wild-
type (+/+) and two homozygous mutant (- / - )
placentas. Conditioned media from the cultures
were collected and tested (at 5 m g/ml) for the
ability to stimulate endothelial cell migration; the
numbers of migrating cells in 10 high-
magnification microscope fields were counted.
Angiogenic activity (mean ± s.e.m. of three
measurements) secreted from wild-type and
heterozygous mutant placentas was similar to the
positive control, 10 ng/ml bFGF. The activity secreted from the homozygous mutant placentas was significantly reduced relative to the wild-
type and heterozygous mutant placentas (P<0.001 in a Student’s t-test). Endothelial cells treated with bovine serum albumin (BSA) served to
determine the background level of migration.
AAAAAAAAAA
AAAAAAAAAA
AAAAAAAAAA
AAAAAAAAAA
AAAAAAAAAA
AAAAAAAAAA
0
5
10
15
20
25
30
35
BSA bFGF +/+
C
el
ls
 M
ig
ra
te
d/
10
 H
P
 F
ie
ld
s
/
- -
+/
-
AAAAAAAAAA
AAAAAAAAAA
AAAAAAAAAA
AAAAAAAAAA
AAAAAAAAAA
AAAAAAAAAA
0
10
20
30
40
50
60
70
C
el
ls
 M
ig
ra
te
d/
10
 H
P
 F
ie
ld
s
BSA bFGF +/+ /
- -
/
- -
A. B.
Fig. 9. Defects in decidual neovascularization. Maternal anti-
mesometrial uterine tissue adjacent to a GATA-2 wild-type placenta
(A) and next to a homozygous mutant placenta (B) within the same
pregnant GATA-2 heterozygous female at day 9.5 were analyzed for
neovascularization by immunostaining (yellow-brown) with an
antibody against the endothelial cell surface marker, PECAM-1. The
decreased decidual neovascularization associated with GATA-2
mutant placentas was detected in all three pregnancies that were
examined. The width of each panel in the figure corresponds to a
distance of 0.3 mm.would be limiting for hormone gene expression in giant cells.
Consistent with this explanation are the observations that both
these factors have an indistinguishable ability to induce tran-
scription from the PL-I promoter in co-transfected trophoblast
cell cultures (Ng et al., 1994), and are equally active in stim-
ulating transcription from the human glycoprotein a -subunit
gene in a transfected pituitary cell line (Steger et al., 1994).
However, unlike the effect on the PLF gene, disruption of the
GATA-2 gene compared to the GATA-3 gene had a similar
impact on PL-I gene expression in vivo. Furthermore, GATA-
2 and GATA-3 mRNA levels in giant cells are very similar (Ng
et al., 1994), suggesting that the concentrations of these two
transcription factors may not be much different in the placenta.
Another possible explanation for the greater effect of the
GATA-2 mutation on PLF mRNA levels is that GATA-2 may
interact more strongly than GATA-3 with cis-regulatory
elements in the PLF gene promoter in vivo, or GATA-2 may
cooperate more effectively with the other transcription factors
that regulate the PLF gene. Such differences in biochemical
activities may mean that GATA-2 and GATA-3 would only
partially complement each other, and therefore these factors
may have distinct roles in placental development. In support of
this possibility is the observation that GATA-2, but not GATA-
3, is uniquely able to stimulate proliferation and block differ-
entiation of erythroid precursors (Briegel et al., 1993).
The fetal lethality that results from a homozygous null
mutation of either the GATA-2 or GATA-3 locus has been
attributed to a direct requirement for these factors in fetal
development (Tsai et al., 1994; Pandolfi et al., 1995). However,
since these factors are also important regulators of placental
hormone synthesis, and quite likely the synthesis of other
placental proteins, a placental defect may also contribute to
fetal death. We have previously demonstrated that the mouse
placenta secretes peak levels of an angiogenic activity at mid-
gestation (day 10). The angiogenic activity is principally due
to PLF protein (Jackson et al., 1994). In the GATA-2 null
mutant, PLF mRNA levels were significantly reduced, sug-
gesting that neovascularization in the conceptus may be com-
promised. Indeed, the total amount of angiogenic secretions
from these mutant placentas, as measured in an endothelial cell
mgration assay, was significantly reduced compared to wild-
type or heterozygous mutant placentas. Furthermore, neovas-
cularization in the uterine decidual tissue next to GATA-2homozygous mutant placentas is significantly reduced
compared to blood vessel growth in the decidual tissue next to
wild-type placentas. Since the decidual tissue is maternal, and
therefore the genotype of the vascular endothelial cells
throughout this tissue is identical, local differences in decidual
neovascularization are not cell autonomous, but instead are
most likely to arise from differences in the levels of angiogenic
factors secreted from the adjacent embryo-derived placenta.
The reduced growth of blood vessels is consistent with the
lower levels of proliferin expression in the mutant placentas,
and therefore these data support a model in which proliferin
diffuses locally from trophoblast giant cells to stimulate uterine
neovascularization. However, angiogenic activity caused by
tissue secretions is typically multi-factorial, with combinations
of angiogenic and anti-angiogenic factors being produced, so
913GATA factors in trophoblaststhe lack of GATA-2 in trophoblasts may have effects on the
expression of multiple genes encoding angiogenesis regulatory
factors in addition to the proliferin gene.
The reduced expression of PLF by the GATA-2 mutant
placenta might have consequences on processes other than
angiogenesis, as well. PLF stimulates uterine cell proliferation
(Nelson et al., 1995), and this hormone enters the fetus where
it binds to specific structures and may participate in fetal devel-
opment (Lee et al., 1988; Jackson and Linzer, 1996). Transport
of this hormone into the fetus may occur preferentially within
a conceptus rather than through the maternal bloodstream, so
the decreased level of PLF protein in one conceptus may not
be compensated for by wild-type levels of hormone secretion
from a neighboring conceptus. In contrast, the known effects
of PL-I are on maternal organs including the ovary and liver
(Ogren and Talamantes, 1988), and thus a lower level of
hormone production from one placenta may be offset by the
secretion of higher levels from other placentas. Some paracrine
effects of PL-I are likely, though, since this hormone can bind
to PRL receptors expressed in the decidual tissue (Gu et al.,
1996), and thus the reduction in PL-I levels in homozygous
GATA-2 mutant conceptuses may also have developmental
consequences even in heterozygous crosses.
Additional effects of GATA-2 and GATA-3 on trophoblast
function may also be revealed as other target genes for these
factors are identified. How these factors may cooperate with
other transcriptional regulators in controlling placental devel-
opment, including the basic helix-loop-helix proteins Hxt,
which has also been shown to stimulate transcription from the
PL-I promoter (Cross et al., 1995), and Mash-2, which is
required for the formation of the spongiotrophoblast cell layer
that underlies and gives rise to the giant cells (Guillemot et al.,
1994), remains to be determined.
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